DZ Bank reiterated their buy rating on shares of Merck KGaA (FRA:MRK) in a research note published on Monday morning, Borsen Zeitung reports.
A number of other research firms have also recently weighed in on MRK. Barclays set a €94.00 ($109.30) price objective on Merck KGaA and gave the company a sell rating in a research report on Monday, January 20th. Goldman Sachs Group set a €94.00 ($109.30) price objective on Merck KGaA and gave the company a sell rating in a research report on Monday. Kepler Capital Markets set a €108.00 ($125.58) price objective on Merck KGaA and gave the company a buy rating in a research report on Wednesday, November 13th. Credit Suisse Group set a €125.00 ($145.35) price objective on Merck KGaA and gave the company a buy rating in a research report on Thursday, January 16th. Finally, JPMorgan Chase & Co. set a €110.00 ($127.91) price objective on Merck KGaA and gave the company a neutral rating in a research report on Wednesday, February 5th. Two analysts have rated the stock with a sell rating, eleven have issued a hold rating and three have given a buy rating to the stock. Merck KGaA currently has a consensus rating of Hold and a consensus price target of €105.47 ($122.64).
MRK stock opened at €122.75 ($142.73) on Monday. Merck KGaA has a twelve month low of €76.60 ($89.07) and a twelve month high of €115.00 ($133.72). The business’s 50-day moving average price is €114.53 and its 200-day moving average price is €104.92.
About Merck KGaA
MERCK Kommanditgesellschaft auf Aktien operates in the healthcare, life science, and performance materials sectors worldwide. It offers prescription medicines to treat cancer, multiple sclerosis, infertility, growth deficiencies, type 2 diabetes, cardiovascular and thyroid diseases, as well as squamous cell carcinoma of the head and neck; diagnostics and prescription drugs for allergen immunotherapy; and fertility treatments.
Receive News & Ratings for Merck KGaA Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Merck KGaA and related companies with MarketBeat.com's FREE daily email newsletter.